Yeahwa Hong

Dr. Yeahwa Hong

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
NHNicholas Ryan Hess
Nicholas Ryan Hess
LSLaura Seese
Laura Seese
YHYeahwa Hong
Yeahwa Hong
DADerek Afflu
Derek Afflu
YWYisi Wang
Yisi Wang
AKArman Kilic
Arman Kilic

8 April 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
KDKeith A. Dufendach
Keith A. Dufendach
TZToby Zhu
Toby Zhu
CCCarlos Diaz Castrillon
Carlos Diaz Castrillon
YHYeahwa Hong
Yeahwa Hong
MCMalamo E. Countouris
Malamo E. Countouris
AKArman Kilic
Arman Kilic

20 January 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
YHYeahwa Hong
Yeahwa Hong
NHNicholas Ryan Hess
Nicholas Ryan Hess
LZLuke A. Ziegler
Luke A. Ziegler
GHGavin W. Hickey
Gavin W. Hickey
JHJessica H. Huston
Jessica H. Huston
DKDavid J Kaczorowski
David J Kaczorowski

19 November 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
YHYeahwa Hong
Yeahwa Hong
NHNicholas Ryan Hess
Nicholas Ryan Hess
ADAnder Dorken-Gallastegi
Ander Dorken-Gallastegi
NINidhi Iyanna
Nidhi Iyanna
GHGavin W. Hickey
Gavin W. Hickey
DKDavid J Kaczorowski
David J Kaczorowski
This study evaluates the impact of the agonal phase and related hemodynamic measures on post-transplant outcomes and heart utilization in donation after circulatory death (DCD) heart transplantation. United Network for Organ Sharing registry was queried to analyze adult recipients who underwent isolated DCD heart transplantation between January 1, 2019 and September 30, 2023. The recipients were stratified into 2 groups based on donor agonal period: <30 and ≥30 minutes. The primary outcome was 90-day post-transplant survival. Propensity score-matching was performed. Sub-analysis was performed to evaluate the association of agonal period with donor heart utilization. Additionally, the associations between different hemodynamic thresholds used to indicate onset of warm ischemia during the agonal phase with 90-day mortality were compared. Eight hundred and eighty nine recipients were included, with 179 (20.1%) receiving hearts from donors with an agonal period of ≥30 minutes. Ninety-day survival (88.1% vs. 95.6%, p < 0.001) was significantly lower among the recipients of donors with an agonal period of ≥30 minutes. The lower 90-day survival persisted in a propensity score-matched comparison. Furthermore, longer agonal periods were associated with reduced donor heart utilization. Lastly, a time interval from a systolic blood pressure of 80 ± 5mmHg to death exhibited significantly higher association with 90-day mortality than a time interval from a systemic oxygen saturation 80 ± 5% to death. Utilizing DCD donor hearts with agonal periods ≥30 minutes is associated with reduced post-transplant survival and decreased donor heart utilization. When assessing the onset of warm ischemia during the agonal phase, hypotension may serve as a more accurate indicator of myocardial ischemia and provide improved post-transplant prognostic insight than hypoxia.

23 February 2024 in Artificial Organs
Verified
Journal Article
Closed access
YHYeahwa Hong
Yeahwa Hong
NANishant Agrawal
Nishant Agrawal
NHNicholas Ryan Hess
Nicholas Ryan Hess
LZLuke A. Ziegler
Luke A. Ziegler
MSMcKenzie M. Sicke
McKenzie M. Sicke
DKDavid J. Kaczorowski
David J. Kaczorowski

11 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
UNUmar Nasim
Umar Nasim
ADAnder Dorken-Gallastegi
Ander Dorken-Gallastegi
PDPeter Dadson
Peter Dadson
YHYeahwa Hong
Yeahwa Hong
Heart transplantation remains the preferred treatment for carefully selected patients with end-stage heart failure refractory to medical therapy. Advances in donor management, organ preservation, donor and recipient selection, immunosuppressive strategies, and mechanical circulatory support have significantly improved the safety and efficacy of heart transplantation. However, the persistent shortage of donor hearts and their limited preservation period continues to restrict access to this lifesaving procedure. The advent of innovative machine perfusion and temperature control systems for heart allograft preservation offers a promising avenue to address these challenges. These technologies aim to extend preservation times and enable the use of extended-criteria donors, thereby expanding the donor pool. In this review, we examine the outcomes from clinical trials, registry data, and single-center studies, utilizing the TransMedics Organ Care System Heart, Paragonix SherpaPak Cardiac Transport System, and XVIVO Heart Preservation System. As the field of heart transplantation evolves to accommodate longer ischemia times, expand organ sharing, and utilize donors previously considered marginal, the integration of these advanced technologies will be essential for optimizing post-transplant outcomes.